No abstract

including 24 (12.4%) pts with 1 serious ADR. 6 pts (3.1%) had AEs leading to Ola discontinuation: 2 anaemia, 2 asthenia, 1 dysgueusia, 1 fatigue, 1 dizziness and 1 hypersensibility. No myelodysplastic syndrome/acute myeloid leukemia was reported and no AE leading to death. Conclusions:We present the first French real-life data through ATUc program with Ola in 1 st L BRCAm. All pts had a BRCA1/2 testing which is routinely performed in France. Olaparib was well tolerated and no new safety signals were observed in this real-life pts population. The enrolment of 201 pts in only 10 months highlights the strong unmet need for mBRCA EOC pts in 1 st L maintenance treatment.Legal entity responsible for the study: AstraZeneca.

No abstract

six cycles. 39% (24/61) of patients inoperable after 3 cycles changed chemotherapy regimens; 42% (10/24) of the latter switched to weekly paclitaxel, 21% (5/24) to bevacizumabbased regimen, and 13% (3/24) to carboplatin + liposomal doxorubcin (Caelyx ® ). 25% (6/24) had palliative aromatase inhibitors or stopped chemo entirely. Of those who had their chemotherapy changed, only 1 patient in bevacizumab group (4%) achieved optimal debulking. Median overall suvival(OS) in those who switched regimen was 17.47 vs 37.40 months in those who did not, p=0.79. Conclusion* Switching chemotherapy regimen in previously inoperable patients did not lead to improved OS. This may reflect the poor prognosis conferred by inadequate response to platinum-based therapy, and needs further evaluation. Though the numbers in each group were small, a change to bevacizumab-based regimen did not appear to improve outcomes. The ICON 8b study will provide further information regarding bevacizumab's role in the neoadjuvant setting.

No abstract